Safety of Nanoparticles in Medicine

ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)


Volume 15, 14 Issues, 2014


Download PDF Flyer




Current Drug Targets

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 52nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.597
5 - Year: 3.558

Safety of Nanoparticles in Medicine

Author(s): Joy Wolfram, Motao Zhu, Yong Yang, Jianliang Shen, Emanuela Gentile, Donatella Paolino, Massimo Fresta, Guangjun Nie, Chunying Chen, Haifa Shen, Mauro Ferrari and Yuliang Zhao

Affiliation: CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience & Technology of China

Abstract

Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles


Purchase Online Rights and Permissions

  
  



Article Details

Volume: 15
First Page: 1
Page Count: 1
DOI: 10.2174/1389450115666140804124808
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science